1. Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. Issue 8 (26th May 2016) Authors: Urup, Thomas; Michaelsen, Signe Regner; Olsen, Lars Rønn; Toft, Anders; Christensen, Ib Jarle; Grunnet, Kirsten; Winther, Ole; Broholm, Helle; Kosteljanetz, Michael; Issazadeh-Navikas, Shohreh; Poulsen, Hans Skovgaard; Lassen, Ulrik Journal: Molecular oncology Issue: Volume 10:Issue 8(2016:Oct.) Page Start: 1160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma. Issue 5 (18th March 2020) Authors: Urup, Thomas; Gillberg, Linn; Kaastrup, Katja; Lü, Maya Jeje Schuang; Michaelsen, Signe Regner; Andrée Larsen, Vibeke; Christensen, Ib Jarle; Broholm, Helle; Lassen, Ulrik; Grønbæk, Kirsten; Poulsen, Hans Skovgaard Journal: Molecular oncology Issue: Volume 14:Issue 5(2020) Page Start: 964 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. (7th February 2018) Authors: Toft, Anders; Urup, Thomas; Christensen, Ib Jarle; Michaelsen, Signe Regner; Lukram, Babloo; Grunnet, Kirsten; Kosteljanetz, Michael; Larsen, Vibeke Andrée; Lassen, Ulrik; Broholm, Helle; Poulsen, Hans Skovgaard Journal: Cancer investigation Issue: Volume 36:Number 2(2018) Page Start: 165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. (2nd April 2016) Authors: Urup, Thomas; Dahlrot, Rikke Hedegaard; Grunnet, Kirsten; Christensen, Ib Jarle; Michaelsen, Signe Regner; Toft, Anders; Larsen, Vibeke Andrée; Broholm, Helle; Kosteljanetz, Michael; Hansen, Steinbjørn; Poulsen, Hans Skovgaard; Lassen, Ulrik Journal: Acta oncologica Issue: Volume 55:Number 4(2016) Page Start: 418 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. EPID-13. IDENTIFICATION OF PROGNOSTIC MARKERS IN A COHORT OF CONSECUTIVE NON-SELECTED GLIOBLASTOMA PATIENTS RECEIVING STANDARD THERAPY. (11th November 2019) Authors: Regner Michaelsen, Signe; Urup, Thomas; Grunnet, Kirsten; Jarle Christensen, Ib; Lassen, Ulrik; Skovgaard Poulsen, Hans Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors. (26th November 2018) Authors: Johansen, Maria Dinche; Urup, Thomas; Holst, Camilla Bjørnbak; Christensen, Ib Jarle; Grunnet, Kirsten; Lassen, Ulrik; Friis, Søren; Poulsen, Hans Skovgaard Journal: Cancer investigation Issue: Volume 36:Number 9/10(2018) Page Start: 512 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PATH-01. IDENTIFICATION OF PROGNOSTIC VARIABLES BASED ON MOLECULAR PROFILING OF LONG-TERM AND SHORT-TERM SURVIVING GLIOBLASTOMA PATIENTS. (6th November 2017) Authors: Michaelsen, Signe Regner; Urup, Thomas; Olsen, Lars Rønn; Gillberg, Linn; Broholm, Helle; Grunnet, Kirsten; Grønbæk, Kirsten; Hamerlik, Petra; Lassen, Ulrik; Poulsen, Hans Skovgaard Journal: Neuro-oncology Issue: Volume 19(2017)Supplement 6 Page Start: vi170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PATH-28. ANGIOTENSINOGEN PROMOTER METHYLATION TO PREDICT BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS. (11th November 2019) Authors: Urup, Thomas; Gillberg, Linn; Kaastrup, Katja; Schuang Lü, Maja; Regner Michaelsen, Signe; Larsen, Vibeke A; Jarle Christensen, Ib; Broholm, Helle; Lassen, Ulrik; Grønbæk, Kirsten; Skovgaard Poulsen, Hans Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET). Issue 12 (6th September 2019) Authors: Bashir, Asma; Mathilde Jacobsen, Sofie; Mølby Henriksen, Otto; Broholm, Helle; Urup, Thomas; Grunnet, Kirsten; Andrée Larsen, Vibeke; Møller, Søren; Skjøth-Rasmussen, Jane; Skovgaard Poulsen, Hans; Law, Ian Journal: Neuro-oncology Issue: Volume 21:Issue 12(2019) Page Start: 1595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. RTID-04. GLIOTARGET: A DANISH NATIONWIDE PHASE I/II PLATFORM TRIAL FOCUSING ON INDIVIDUALIZED TARGETED TREATMENT FOR NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS BASED ON GENOMIC PROFILING. (12th November 2021) Authors: Fougner, Vincent; Hasselbalch, Benedikte; Urup, Thomas; Lassen, Ulrik; Poulsen, Hans Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗